From:  Immune checkpoint inhibitors in patients with advanced gastric cancer: a multi-institutional retrospective real-world study

Univariate analysis of overall survival in patients with MSI-H

Risk factors and categoryN, %HR, (95% CI)P
All27
Age< 65
≥ 65		15
12		0.78 (0.27–2.21)0.649
GenderMale
Female		13
14		0.93 (0.33–2.59)0.900
ECOG0–1
2–3		20
7		4.34 (1.50–13.49)0.007
Histology gradeG1–G2
G3
NA		8
18
1		2.00 (0.62–6.45)0.243
Signet-ring cells in histologyNo
Yes
NA		6
11
10		1.65 (0.41–6.65)0.475
Presence of primary tumorNo
Yes		16
11		0.94 (0.33–2.66)0.910
Number of organs with metastases1–2
≥ 3		22
5		1.99 (0.70–5.63)0.195
AscitesNo
Yes		17
10		1.32 (0.47–3.74)0.592
Peritoneal carcinomatosisNo
Yes		17
10		0.84 (0.28–2.49)0.765
Bone metastasesNo
Yes		24
3		1.30 (0.29–5.79)0.727
PainNo
Yes		20
7		3.93 (1.34–11.49)0.012
Line of immunotherapyI–II
III–IV		13
11		2.16 (0.67–6.99)0.196
NLR< 1.8
≥ 1.8		6
8		4.08 (0.80–20.76)0.090
Return to article view

MSI-H: high microsatellite instability; ECOG: Eastern Cooperative Oncology Group; NLR: neutrophil-lymphocyte ratio